Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight

Biochemical and Biophysical Research Communications

Volumn 271, Issue 2, 2000, Pages 445-450

  Chaput, Evelyne ^a   Saladin, Reégis ^a   Silvestre, Martine ^a   Edgar, Alan D ^a  

^a Laboratoires Fournier SA   (France)

Author keywords

Diabetes; Fenofibrate; Peroxisome proliferator activated receptor; Rosiglitazone; Weight gain

Indexed keywords

ACYL COENZYME A OXIDASE; FENOFIBRATE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; DIABETES MELLITUS; GENE EXPRESSION; INSULIN BLOOD LEVEL; LIVER; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANIMALIA;

EID: 0034630720     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2000.2647     Document Type: Article

References (21)

1. Brewer, H. B., Jr. (1999) Hypertriglyceridemia: Changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am. J. Cardiol. 83, 3F-12F.
2. Schoonjans, K., Staels, B., and Auwerx, J. (1996) Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37, 907-925.
3. Balfour, J. A., McTavish, D., and Heel, R. C. (1990) Fenofibrate, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidemia. Drugs 40, 260-290.
4. Gotto, A. M., Jr. (1998) Triglyceride as a risk factor for coronary artery disease. Am. J. Cardiol. 82, 22Q-25Q.
5. Staels, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Torra, I. P., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J. C., Najib, J., Maclouf, J., and Tedgui, A. (1998) Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPAR-gamma activators. Nature 393, 790-793.
6. Chinetti, G., Griglio, S., Antonucci, M., Torra, I. P., Delerive, P., Majd, Z., Fruchart, J. C., Chapman, J., Najib, J., and Staels, B. (1998) Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273, 25573-25580.
7. Inoue, I., Shino, K., Noji, S., Awata, T., and Katayama, S. (1998) Expression of peroxisome proliferator-activated receptor α (PPAR α) in primary cultures of human vascular endothelial cells. Biochem. Biophys. Res. Commun. 246, 370-374.
8. Saltiel, A. R., and Olefsky, J. M. (1996) Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45, 1661-1669.
9. Marx, N., Bourcier, T., Sukhova, G. K., Libby, P., and Plutzky, J. (1999) PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 19, 546-551.
10. Marx, N., Schonbeck, U., Lazar, M. A., Libby, P., and Plutzky, J. (1998) Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83, 1097-1103.
11. Tontonoz, P., Hu, E., and Spiegelman, B. M. (1995) Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr. Opin. Genet. Dev. 5, 571-576.
12. Steiner, G. (1996) The Diabetes Atherosclerosis Intervention Study (DAIS): A study conducted in cooperation with the World Health Organization. The DAIS Project Group. Diabetologia 39, 1655-1661.
13. van Zwieten, P. A. (1999) Diabetes and hypertension: Experimental models for pharmacological studies. Clin. Exp. Hypertens. 21, 1-16.
14. Kim, J. H., Nishina, P. M., and Naggert, J. K. (1998) Genetic models for non insulin dependent diabetes mellitus in rodents. J. Basic Clin. Physiol. Pharmacol. 9, 325-345.
15. Lefebvre, A. M., Peinado-Onsurbe, J., Leitersdorf, I., Briggs, M. R., Paterniti, J. R., Fruchart, J. C., Fievet, C., Auwerx, J., and Staels, B. (1997) Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler. Thromb. Vasc. Biol. 17, 1756-1764.
16. Murakami, K., Tobe, K., Ide, T., Mochizuki, T., Ohashi, M., Akanuma, Y., Yazaki, Y., and Kadowaki, T. (1998) A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: Effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 47, 1841-1847.
17. Saladin, R., Vu Dac, N., Fruchart, J. C., Auwerx, J., and Staels, B. (1996) Transcriptional induction of rat liver apolipoprotein A-I gene expression by glucocorticoids requires the glucocorticoid receptor and a labile cell-specific protein. Eur. J. Biochem. 239, 451-459.
18. Costet, P., Legendre, C., More, J., Edgar, A., Galtier, P., and Pineau, T. (1998) Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J. Biol. Chem. 273, 29577-29585.
19. De Vos, P., Lefebvre, A. M., Miller, S. G., Guerre-Millo, M., Wong, K., Saladin, R., Hamann, L. G., Staels, B., Briggs, M. R., and Auwerx, J. (1996) Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J. Clin. Invest. 98, 1004-1009.
20. Edvardsson, U., Bergstrom, M., Alexandersson, M., Bamberg, K., Ljung, B., and Dahllof, B. (1999) Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J. Lipid Res. 40, 1177-1184.
21. Hirshman, M. F., Fagnant, P. M., Horton, E. D., King, P. A., and Horton, E. S. (1995) Pioglitazone treatment for 7 days failed to correct the defect in glucose transport and glucose transporter translocation in obese Zucker rat (fa/fa) skeletal muscle plasma membranes. Biochem. Biophys. Res. Commun. 208, 835-845.